WP
ADCT icon

Woodline Partners’s ADC Therapeutics ADCT Stock Holding History

Woodline Partners’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-842,900
Closed -$2.26M – 872
2025
Q2 		$2.26M Buy
842,900
+27,369
+3% +$57.6K 0.01% 706
2025
Q1 		$1.15M Sell
815,531
-1,118,220
-58% -$1.9M 0.01% 752
2024
Q4 		$3.85M Buy
+1,933,751
New +$5.06M 0.03% 538
2023
Q2 		– Sell
-143,403
Closed -$280K – 622
2023
Q1 		$280K Buy
+143,403
New +$529K ﹤0.01% 564
2022
Q4 		– Sell
-47,567
Closed -$229K – 748
2022
Q3 		$229K Buy
47,567
+13,726
+41% +$99.4K ﹤0.01% 642
2022
Q2 		$269K Buy
+33,841
New +$320K ﹤0.01% 599

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Woodline Partners's ADCT Position: Q3 2025 in Review

Woodline Partners sold out of ADC Therapeutics (ADCT) in Q3 2025, closing a stake of 842,900 shares — an estimated $2.26M sold.

Woodline Partners first reported a position in ADCT in Q2 2022 and held it in 6 quarters. The position peaked at $3.85M in Q4 2024. 106 funds tracked by Wall St. Rank hold ADCT as of Q3 2025.

  • Woodline Partners reported no remaining ADC Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Woodline Partners sold 842,900 ADC Therapeutics shares in Q3 2025, an estimated $2.26M.
  • Woodline Partners first reported a position in ADC Therapeutics in Q2 2022 and held it in 6 quarters.
  • Woodline Partners's ADC Therapeutics position peaked at $3.85M in Q4 2024.
  • 106 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2025.

Based on Woodline Partners's 13F filing for Q3 2025, filed 14 Nov 2025.